Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1
(1)
,
(2)
,
(3)
,
(4)
,
(5)
,
(6)
,
(7)
,
(7)
,
(8)
,
(7)
,
(7)
,
(7)
,
(7)
,
(9)
,
(10)
,
(11)
,
,
(12)
,
(13)
,
(14)
,
(15)
,
(16)
,
(17)
,
(18)
,
(19)
,
(20)
,
(21)
,
(22)
,
(23)
,
(24)
,
(25)
,
(26)
,
(27)
,
(28)
,
(29)
,
(30)
,
(31)
,
(32)
,
(33)
,
(34)
,
(35)
,
(36)
,
(37)
,
(38)
,
(38)
,
(39)
,
(40)
,
(41)
,
(42)
,
(43)
,
(44)
,
(45)
,
(46)
,
(47)
,
(48)
,
(49)
,
(4)
,
(50)
,
(51)
,
(52)
,
(53)
,
(54)
,
(55)
,
(56)
,
(57)
,
(58)
,
(59)
,
(60)
,
(61)
,
(2)
,
(62)
,
(63)
,
(64)
,
(65)
,
(66)
,
(67)
,
(68)
,
(69)
,
(70)
,
(3)
,
(71)
,
(72)
,
,
(73)
,
,
,
,
,
(74)
,
,
(75)
,
(76)
,
(77)
,
(78)
,
(79)
,
(80)
,
(81)
,
(82)
,
(83)
,
(84)
,
(85)
,
(86)
,
(87)
,
(88)
,
(89)
,
(90)
,
(91)
,
(92)
,
(93)
,
(94)
,
(95)
,
(96)
,
(97)
,
(98)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
I.Santos Gil
- Function : Author
Isabelle Poizot-Martin
- Function : Author
- PersonId : 21118
- IdHAL : isabelle-poizot-martin
- ORCID : 0000-0002-5676-5411
- IdRef : 059519045
Jacques Reynes
- Function : Author
- PersonId : 931001
Yazdan Yazdanpanah
- Function : Author
- PersonId : 993665
Franco Felizarta
- Function : Author
Joel Gallant
- Function : Author
Joseph Gathe
- Function : Author
Debbie Hagins
- Function : Author
Sarah Henn
- Function : Author
Gregory D Huhn
- Function : Author
Abstract
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated through 96 weeks in EMERALD (NCT02269917).
Virologically-suppressed, HIV-1-positive treatment-experienced adults (previous non-darunavir virologic failure [VF] allowed) were randomized (2:1) to D/C/F/TAF or boosted protease inhibitor (PI) plus emtricitabine/tenofovir-disoproxil-fumarate (F/TDF) over 48 weeks. At week 52 participants in the boosted PI arm were offered switch to D/C/F/TAF (late-switch, 44 weeks D/C/F/TAF exposure). All participants were followed on D/C/F/TAF until week 96. Efficacy endpoints were percentage cumulative protocol-defined virologic rebound (PDVR; confirmed viral load [VL] ≥50 copies/mL) and VL < 50 copies/mL (virologic suppression) and ≥50 copies/mL (VF) (FDA-snapshot analysis).
Of 1141 randomized patients, 1080 continued in the extension phase. Few patients had PDVR (D/C/F/TAF: 3.1%, 24/763 cumulative through week 96; late-switch: 2.3%, 8/352 week 52–96). Week 96 virologic suppression was 90.7% (692/763) (D/C/F/TAF) and 93.8% (330/352) (late-switch). VF was 1.2% and 1.7%, respectively. No darunavir, primary PI, tenofovir or emtricitabine resistance-associated mutations were observed post-baseline. No patients discontinued for efficacy-related reasons. Few discontinued due to adverse events (2% D/C/F/TAF arm). Improved renal and bone parameters were maintained in the D/C/F/TAF arm and observed in the late-switch arm, with small increases in total cholesterol/high-density-lipoprotein-cholesterol ratio. A study limitation was the lack of a control arm in the week 96 analysis.
Through 96 weeks, D/C/F/TAF resulted in low PDVR rates, high virologic suppression rates, very few VFs, and no resistance development. Late-switch results were consistent with D/C/F/TAF week 48 results. EMERALD week 96 results confirm the efficacy, high genetic barrier to resistance and safety benefits of D/C/F/TAF.
Origin : Publication funded by an institution
Loading...